ArQule Company Profile (NASDAQ:ARQL)

About ArQule

ArQule logoArQule, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations. The Company's lead product candidate is tivantinib (ARQ 197), an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase (MET) and its biological pathway. The Company's product candidates include ARQ 092, designed to inhibit the AKT serine/threonine kinase; ARQ 087, a multi-kinase inhibitor designed to inhibit the fibroblast growth factor receptor (FGFR) family, and ARQ 761, a Beta lapachone analog being evaluated in investigator-sponsored testing as a promoter of NQO1-mediated programmed cancer cell necrosis.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ARQL
  • CUSIP: 04269E10
Key Metrics:
  • Previous Close: $1.57
  • 50 Day Moving Average: $1.50
  • 200 Day Moving Average: $1.63
  • 52-Week Range: $71,106,000.00 - $1.37
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.60
  • P/E Growth: -0.95
  • Market Cap: $117.32M
  • Outstanding Shares: 71,106,000
  • Beta: 1.28
Profitability:
  • Net Margins: -197.25%
  • Return on Equity: -44.89%
  • Return on Assets: -34.45%
Debt:
  • Current Ratio: 5.10%
  • Quick Ratio: 5.10%
Additional Links:
Companies Related to ArQule:

Analyst Ratings

Consensus Ratings for ArQule (NASDAQ:ARQL) (?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $3.75 (127.27% upside)

Analysts' Ratings History for ArQule (NASDAQ:ARQL)
Show:
DateFirmActionRatingPrice TargetDetails
3/1/2016Leerink SwannLower Price TargetMarket Perform$3.00 -> $2.50View Rating Details
12/27/2015Royal Bank Of CanadaUpgradeBuyView Rating Details
(Data available from 9/26/2014 forward)

Earnings

Earnings History for ArQule (NASDAQ:ARQL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2016        
8/3/2016Q216($0.08)($0.07)$1.13 million$1.07 millionViewN/AView Earnings Details
5/4/2016Q116($0.07)($0.08)$1.63 million$1.28 millionViewN/AView Earnings Details
2/29/2016Q415($0.06)($0.05)$2.40 million$2.80 millionViewListenView Earnings Details
11/4/2015Q315($0.08)($0.04)$2.60 million$2.65 millionViewN/AView Earnings Details
8/5/2015Q215($0.08)($0.06)$2.50 million$3.04 millionViewN/AView Earnings Details
5/6/2015Q115($0.08)($0.07)$1.98 million$2.79 millionViewN/AView Earnings Details
3/4/2015Q414($0.13)($0.06)$1.90 million$3.02 millionViewN/AView Earnings Details
11/10/2014Q314($0.13)($0.10)$2.20 million$2.66 millionViewN/AView Earnings Details
8/5/2014Q214($0.12)($0.10)$2.43 million$2.90 millionViewN/AView Earnings Details
5/7/2014Q114($0.11)($0.11)$2.29 million$2.67 millionViewN/AView Earnings Details
3/5/2014Q413($0.13)($0.10)$2.27 million$2.28 millionViewN/AView Earnings Details
10/31/2013Q313($0.13)($0.10)$2.77 million$3.50 millionViewN/AView Earnings Details
7/30/2013Q2 2013($0.12)($0.11)$3.84 million$4.44 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.11)($0.09)$3.78 million$5.66 millionViewN/AView Earnings Details
3/14/2013Q4 2012($0.13)($0.09)$5.17 million$5.14 millionViewN/AView Earnings Details
11/1/2012($0.07)($0.01)ViewN/AView Earnings Details
8/2/2012($0.07)($0.01)ViewN/AView Earnings Details
5/3/2012($0.07)($0.08)ViewN/AView Earnings Details
3/1/2012($0.09)$0.07ViewN/AView Earnings Details
11/10/2011($0.23)($0.04)ViewN/AView Earnings Details
8/4/2011($0.19)($0.20)ViewN/AView Earnings Details
5/5/2011($0.08)($0.03)ViewN/AView Earnings Details
3/1/2011($0.15)($0.13)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ArQule (NASDAQ:ARQL)
Current Year EPS Consensus Estimate: $-0.33 EPS
Next Year EPS Consensus Estimate: $-0.25 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.08)($0.08)($0.08)
Q2 20161($0.08)($0.08)($0.08)
Q3 20161($0.09)($0.09)($0.09)
Q4 20161($0.10)($0.10)($0.10)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for ArQule (NASDAQ:ARQL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for ArQule (NASDAQ:ARQL)
Insider Ownership Percentage: 8.30%
Institutional Ownership Percentage: 58.16%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/17/2015Michael D LobergDirectorBuy3,719$2.16$8,033.04View SEC Filing  
12/16/2015Michael D LobergDirectorBuy1,231$2.14$2,634.34View SEC Filing  
12/15/2015Paolo PucciCEOBuy1,283$2.16$2,771.28View SEC Filing  
12/11/2015Paolo PucciCEOBuy1,108$2.10$2,326.80View SEC Filing  
12/11/2015Patrick J ZennerDirectorBuy2,300$2.15$4,945.00View SEC Filing  
12/10/2015Paolo PucciCEOBuy7,609$2.10$15,978.90View SEC Filing  
3/11/2015Patrick J ZennerDirectorBuy10,625$2.32$24,650.00View SEC Filing  
11/20/2014Paolo PucciCEOBuy5,000$1.26$6,300.00View SEC Filing  
11/14/2014Patrick J ZennerDirectorBuy20,830$1.20$24,996.00View SEC Filing  
11/13/2014Susan L KelleyDirectorBuy50,000$1.20$60,000.00View SEC Filing  
9/4/2014Paolo PucciCEOBuy5,000$1.31$6,550.00View SEC Filing  
5/23/2014Paolo PucciCEOBuy5,000$1.40$7,000.00View SEC Filing  
5/20/2014Paolo PucciCEOBuy5,000$1.42$7,100.00View SEC Filing  
3/17/2014Patrick ZennerDirectorBuy4,715$2.12$9,995.80View SEC Filing  
3/13/2014Paolo PucciCEOBuy10,000$2.10$21,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for ArQule (NASDAQ:ARQL)
DateHeadline
News IconKeen Investors Find News on ArQule Inc. (NASDAQ:ARQL) - Duncan Research (NASDAQ:ARQL)
www.duncanindependent.com - September 24 at 3:30 PM
News IconUnder the Microscope, Zeroing in at ArQule Inc. (NASDAQ:ARQL) - Duncan Research (NASDAQ:ARQL)
www.duncanindependent.com - September 23 at 8:28 AM
News IconPenny Stock Investors Keen on Shares of ArQule Inc. (NASDAQ:ARQL) - Duncan Research (NASDAQ:ARQL)
www.duncanindependent.com - September 21 at 4:29 PM
kcregister.com logoStock Highlights: ArQule Inc. (NASDAQ:ARQL), Navios Maritime Holdings Inc. (NYSE:NM), Merck & Co., (NYSE:MRK ... - KC Register (NASDAQ:ARQL)
www.kcregister.com - September 21 at 8:40 AM
News IconPenny Stock Investors Take an Interest in ArQule Inc. (NASDAQ:ARQL) - Duncan Research (NASDAQ:ARQL)
www.duncanindependent.com - September 21 at 8:40 AM
finance.yahoo.com logoArQule to Present at The Leerink Partners Rare Disease and Immuno-Oncology Roundtable on September 28, 2016 (NASDAQ:ARQL)
finance.yahoo.com - September 21 at 8:40 AM
capitalcube.com logoETF’s with exposure to ArQule, Inc. : September 19, 2016 (NASDAQ:ARQL)
www.capitalcube.com - September 19 at 4:31 PM
capitalcube.com logoETF’s with exposure to ArQule, Inc. : September 19, 2016 (NASDAQ:ARQL)
www.capitalcube.com - September 19 at 4:31 PM
News IconKeen Investors Seek Information on ArQule Inc. (NASDAQ:ARQL) - Duncan Research (NASDAQ:ARQL)
www.duncanindependent.com - September 17 at 8:23 AM
News IconStock Update, a Closer Look at ArQule Inc. (NASDAQ:ARQL) - Duncan Research (NASDAQ:ARQL)
www.duncanindependent.com - September 15 at 8:43 PM
businesswire.com logoArQule Announces Publication of Manuscript Highlighting Preclinical Activity of FGFR Inhibitor, ARQ 087, in Peer ... - Business Wire (press release) (NASDAQ:ARQL)
www.businesswire.com - September 15 at 12:29 PM
finance.yahoo.com logoArQule Announces Publication of Manuscript Highlighting Preclinical Activity of FGFR Inhibitor, ARQ 087, in Peer Reviewed Journal (NASDAQ:ARQL)
finance.yahoo.com - September 15 at 12:29 PM
finance.yahoo.com logo7:01 am ArQule announces the publication detailing the preclinical profile of ARQ 087 by PLOS ONE; demonstrate that ARQ 087 has anti-proliferative activity in cell lines driven by FGFR dysregulation, including amplifications, fusions, and m (NASDAQ:ARQL)
finance.yahoo.com - September 15 at 12:29 PM
News IconKeen Investors Narrowing Their Focus on ArQule Inc. (NASDAQ:ARQL) - Duncan Research (NASDAQ:ARQL)
www.duncanindependent.com - September 14 at 3:36 PM
News IconPenny Stock Investors Highly Curious in Shares of ArQule Inc. (NASDAQ:ARQL) - Duncan Research (NASDAQ:ARQL)
www.duncanindependent.com - September 13 at 3:35 PM
News IconArQule, Inc. (NASDAQ:ARQL): How Are Analysts Advising to Play This Stock? - Post News (NASDAQ:ARQL)
www.kentuckypostnews.com - September 13 at 3:35 PM
capitalcube.com logoETF’s with exposure to ArQule, Inc. : September 8, 2016 (NASDAQ:ARQL)
www.capitalcube.com - September 8 at 10:31 AM
News IconWall Street Consensus Opinions for: NL Industries, Inc. (NYSE:NL) , ArQule, Inc. (NASDAQ:ARQL) - Wall Street Times (press release) (NASDAQ:ARQL)
www.wallstreetnews24.com - September 2 at 8:14 AM
News IconPT Look at ArQule, Inc. (NASDAQ:ARQL) - Post News (NASDAQ:ARQL)
www.kentuckypostnews.com - August 30 at 10:48 AM
capitalcube.com logoETF’s with exposure to ArQule, Inc. : August 25, 2016 (NASDAQ:ARQL)
www.capitalcube.com - August 25 at 3:37 PM
News IconPrice Target Update on ArQule, Inc. (NASDAQ:ARQL) - Post News (NASDAQ:ARQL)
www.kentuckypostnews.com - August 23 at 7:09 AM
News IconStock Tracking Lower for the Quarter: ArQule Inc. (NASDAQ:ARQL) - Post News (NASDAQ:ARQL)
www.kentuckypostnews.com - August 21 at 8:21 AM
investornewswire.com logoWill ArQule, Inc. (NASDAQ:ARQL) Hit $5 Price Target? - Investor Newswire (NASDAQ:ARQL)
www.investornewswire.com - August 19 at 4:12 PM
News IconStock Monitor: PT Update on ArQule, Inc. (NASDAQ:ARQL) - Post News (NASDAQ:ARQL)
www.kentuckypostnews.com - August 18 at 11:59 AM
News IconShares Moving Up to a Recent High: ArQule Inc. (NASDAQ:ARQL) - Post News (NASDAQ:ARQL)
www.kentuckypostnews.com - August 16 at 3:37 PM
News IconSell-side Spotlight on ArQule, Inc. (NASDAQ:ARQL) - Post News (NASDAQ:ARQL)
www.kentuckypostnews.com - August 16 at 3:37 PM
capitalcube.com logoETF’s with exposure to ArQule, Inc. : August 11, 2016 (NASDAQ:ARQL)
www.capitalcube.com - August 11 at 12:50 PM
finance.yahoo.com logoARQULE INC Financials (NASDAQ:ARQL)
finance.yahoo.com - August 6 at 3:53 PM
capitalcube.com logoArQule, Inc. :ARQL-US: Earnings Analysis: Q2, 2016 By the Numbers : August 5, 2016 (NASDAQ:ARQL)
www.capitalcube.com - August 5 at 3:36 PM
finance.yahoo.com logoEdited Transcript of ARQL earnings conference call or presentation 3-Aug-16 1:00pm GMT (NASDAQ:ARQL)
finance.yahoo.com - August 3 at 9:15 PM
rttnews.com logoEARNINGS SUMMARY: Details of ArQule Inc. Q2 Earnings Report (NASDAQ:ARQL)
www.rttnews.com - August 3 at 12:09 PM
finance.yahoo.com logoArQule reports 2Q loss (NASDAQ:ARQL)
finance.yahoo.com - August 3 at 12:09 PM
News IconArQule Reports Second Quarter 2016 Financial Results (NASDAQ:ARQL)
www.cbs58.com - August 3 at 12:09 PM
biz.yahoo.com logoARQULE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (NASDAQ:ARQL)
biz.yahoo.com - August 3 at 12:09 PM
investornewswire.com logoCan Shares Of ArQule, Inc. (NASDAQ:ARQL) Hit $5? - Investor Newswire (NASDAQ:ARQL)
www.investornewswire.com - July 29 at 3:35 PM
News IconChecking in on Stock Volatility for: ArQule Inc. (NASDAQ:ARQL) - Engelwood Daily (NASDAQ:ARQL)
www.engelwooddaily.com - July 21 at 3:35 PM
News IconWere Analysts Bullish ArQule, Inc. (NASDAQ:ARQL) This Week? - Consumer Eagle (NASDAQ:ARQL)
www.consumereagle.com - July 20 at 11:02 PM
finance.yahoo.com logoArQule To Report Second Quarter 2016 Financial Results On August 3, 2016 (NASDAQ:ARQL)
finance.yahoo.com - July 20 at 7:00 AM
streetinsider.com logoArQule (ARQL) Announces Presentation of ARQ 531 Preclinical Data - StreetInsider.com (NASDAQ:ARQL)
www.streetinsider.com - July 19 at 3:34 PM
News IconArqule Incorporated (NASDAQ:ARQL) Shorts Decreased by 4.65% After Short Covering - Press Telegraph (NASDAQ:ARQL)
presstelegraph.com - July 19 at 3:34 PM
finance.yahoo.com logoArQule Presents Preclinical Data for ARQ 531, a Proprietary Reversible Inhibitor of Wild Type and Mutant BTK, at the 2016 Pan Pacific Lymphoma Conference (NASDAQ:ARQL)
finance.yahoo.com - July 18 at 4:00 PM
investornewswire.com logoStrong Sell Calls For ArQule, Inc. (NASDAQ:ARQL) At 0 - Investor Newswire (NASDAQ:ARQL)
www.investornewswire.com - July 15 at 7:51 PM
News IconShares Experiencing a Downtrend: ArQule Inc. (NASDAQ:ARQL) - TGP (NASDAQ:ARQL)
telanaganapress.com - July 15 at 7:51 PM
ftsenews.co.uk logoArQule, Inc. (ARQL) Updated Price Targets - FTSE News (NASDAQ:ARQL)
www.ftsenews.co.uk - July 13 at 3:38 PM
News IconHow Analysts Feel About ArQule, Inc. (NASDAQ:ARQL)? - Consumer Eagle (NASDAQ:ARQL)
www.consumereagle.com - July 12 at 9:05 PM
News IconConsensus Target and Stock Rating Report: ArQule, Inc. (NASDAQ:ARQL) - Telanagana Press (NASDAQ:ARQL)
telanaganapress.com - July 12 at 7:17 AM
News IconArqule Incorporated (NASDAQ:ARQL) Sellers Increased By 13.75% Their Shorts - Press Telegraph (NASDAQ:ARQL)
presstelegraph.com - July 9 at 11:38 AM
investornewswire.com logoIs $5 Within Reach For ArQule, Inc. (NASDAQ:ARQL)? - Investor Newswire (NASDAQ:ARQL)
www.investornewswire.com - July 8 at 8:44 PM
kcregister.com logoEye Catching Stocks: ArQule Inc. (NASDAQ:ARQL), Dehaier Medical Systems Limited (NASDAQ:DHRM), Lipocine Inc ... - KC Register (NASDAQ:ARQL)
www.kcregister.com - July 8 at 3:35 PM
kcregister.com logoBullish Movers: SemiLEDs Corporation (NASDAQ:LEDS), ArQule Inc. (NASDAQ:ARQL), China Commercial Credit, Inc ... - KC Register (NASDAQ:ARQL)
www.kcregister.com - July 8 at 3:35 PM

Social

ArQule (NASDAQ:ARQL) Chart for Monday, September, 26, 2016


Last Updated on 9/26/2016 by MarketBeat.com Staff